Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Total monthly reach
Estimated from 5 chart positions in 5 markets.
By chart position
- 🇸🇦SA · Courses#703K to 10K
- 🇳🇿NZ · Courses#713K to 10K
- 🇨🇭CH · Courses#119500 to 3K
- 🇦🇪AE · Courses#164500 to 3K
- 🇳🇬NG · Courses#178500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
3.8K to 15K🎙 Weekly cadence·16 episodes·Last published today - Monthly Reach
Unique listeners across all episodes (30 days)
7.5K to 29K🇸🇦34%🇳🇿34%🇨🇭10%+2 more - Active Followers
Loyal subscribers who consistently listen
2.3K to 8.7K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
Recent episodes
Dexcom G7 Sensor Recall: Check These Two Lot Numbers
Jun 1, 2026
4m 20s
Fatty Liver May Be a Heart Warning
May 29, 2026
4m 28s
What Happens When You Stop Tirzepatide?
May 25, 2026
4m 01s
Spotting Type 1 Diabetes in Kids Before Symptoms
May 22, 2026
3m 58s
Medical News Update The Breakthrough Wegovy Weight Loss Pill
May 12, 2026
2m 55s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Description | Length | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 6/1/26 |  Dexcom G7 Sensor Recall: Check These Two Lot Numbers | Two lots of Dexcom G7 sensors were stolen before destruction and resold. Check lot numbers 1725204004 and 1725069002. Here's what to do.A safety alert for anyone using a Dexcom G7 continuous glucose monitor. On May 26, 2026, Dexcom revealed that sensors marked for destruction were stolen and resold through unauthorized channels. This is NOT a warning about every G7 sensor — it affects two specific lot numbers. We walk through exactly what to check and what to do.In this episode:• The two affected lot numbers — 1725204004 and 1725069002 — read slowly so you can check• Why one lot has a sterilization concern (skin infection risk) and the other a higher failure rate• How to find the lot number on your sensor packaging• What to do if you have an affected sensor — and how to get a free replacement• Why this is NOT a blanket recall of all G7 sensorsKey takeaway: Check your Dexcom G7 packaging against lot numbers 1725204004 and 1725069002. If yours matches, don't use it — contact Dexcom for a replacement and use a backup glucose check if needed. Don't change any medication based on this news alone.Disclaimer: This podcast is for general education only. It is not medical advice. Always consult your diabetes care team. If you have signs of severe high or low glucose, diabetic ketoacidosis, or a serious skin infection, seek urgent care.Show notes / sources:Dexcom theft notice (BusinessWire)Australian TGA market action — Dexcom G7 sensorsNDSS recall alertMedTech Dive coverage#Dexcom #DexcomG7 #CGM #DiabetesTech #ContinuousGlucoseMonitor #Recall #DiabetesSafety #Type1Diabetes #MedicalNewsUpdate | 4m 20s | ||||||
| 5/29/26 | Fatty Liver May Be a Heart Warning | A Mass General Brigham study links fatty liver to a 69% higher relative risk of major heart events. Why your liver is talking to your heart.Fatty liver disease — now called MASLD — is everywhere. As many as 1 in 3 American adults have some degree of it, often without knowing. For years, doctors treated it as a liver problem. A new Mass General Brigham study, using cardiac CT scans of 3,637 patients from the PROMISE trial, shows we've been thinking about it wrong. People with fatty liver had more unstable artery plaque, and a 69% higher relative risk of heart attacks, strokes, or cardiac death over the following two years.In this episode:• What fatty liver (MASLD) actually is and why it's so common• How researchers used heart CT scans to spot fatty liver "for free"• Why noncalcified plaque is the more dangerous kind• The absolute risk difference: 4.1% vs 2.5% over two years• Why diabetes, prediabetes, and abdominal weight raise the stakes• How the same lifestyle changes treat both fatty liver and heart riskKey takeaway: Your liver and your heart are not separate stories. If a doctor has ever mentioned fatty liver, the next question is — what are my heart-risk numbers? Blood pressure. LDL cholesterol. A1C. Don't wait for an event to find out.Disclaimer: This podcast is for general education only. It is not medical advice. Always consult your doctor.#FattyLiver #MASLD #HeartDisease #Cardiovascular #Diabetes #MetabolicHealth #InsulinResistance #PROMISETrial #MedicalNewsUpdate | 4m 28s | ||||||
| 5/25/26 | What Happens When You Stop Tirzepatide? | The SURMOUNT-MAINTAIN trial answers what happens after you stop Mounjaro or Zepbound — and offers a lower-dose maintenance option that mostly held weight off.Tirzepatide — the drug you know as Mounjaro for diabetes and Zepbound for weight loss — has produced some of the biggest weight-loss numbers we have ever seen. But everyone asks the same question: what happens when you stop? A new trial called SURMOUNT-MAINTAIN, published in The Lancet, finally gives us a clean answer. People who continued the drug kept most of the weight off. People who stopped regained much of it back.In this episode:• The full SURMOUNT-MAINTAIN trial design — 441 adults, three groups• How the full dose, the 5 mg maintenance dose, and placebo compared at week 112• Why obesity behaves like a long-term condition — not a short-term problem• The "weight set point" — and why your body fights to climb back up• When a lower maintenance dose might be the smarter long-term choice• Important limitation — people with type 2 diabetes were NOT in this trialKey takeaway: For tirzepatide to keep working, it likely needs to stay on board long-term. Maintenance dosing is now a real, evidence-backed option — but never stop, lower, or restart on your own.Disclaimer: This podcast is for general education only. It is not medical advice. Always consult your doctor.#Tirzepatide #Mounjaro #Zepbound #WeightLoss #SURMOUNTMAINTAIN #GLP1 #Obesity #WeightMaintenance #Lancet #MedicalNewsUpdate | 4m 01s | ||||||
| 5/22/26 | Spotting Type 1 Diabetes in Kids Before Symptoms | A German JAMA study screened 220,000+ children for early type 1 diabetes during normal pediatric visits—catching it years before symptoms appear.For most families, type 1 diabetes shows up out of nowhere — sometimes as a child rushed to the emergency room in diabetic ketoacidosis. But a huge new study from Germany, published in JAMA, suggests we can do much better. Pediatricians in Bavaria screened more than 220,000 children for early-stage type 1 diabetes during routine office visits — catching the disease quietly building, years before symptoms ever appeared.In this episode:• What "early-stage" type 1 diabetes really means• How the Fr1da program ran through 716 community pediatricians from 2015–2025• Why 81% of children who later developed full type 1 diabetes were already flagged• The annual progression rate from early markers to clinical diabetes• Why most type 1 families have no warning — and how screening could change that• What this does NOT mean for testing on your ownKey takeaway: Type 1 diabetes is not as unpredictable as we once thought. Early antibody screening in routine pediatric care can buy families precious time and may prevent the medical emergency that still introduces many children to the diagnosis.Disclaimer: This podcast is for general education only. It is not medical advice. Always consult your doctor.#Type1Diabetes #PediatricHealth #DiabetesScreening #DKA #Autoantibodies #JAMA #Fr1da #ChildHealth #MedicalNewsUpdate | 3m 58s | ||||||
| 5/12/26 | Medical News Update The Breakthrough Wegovy Weight Loss Pill | FDA Approves Wegovy Weight-Loss Pill: What to Know About Oral SemaglutideThis episode explains the first FDA-approved GLP-1 weight-loss drug in pill form: a once-daily oral semaglutide tablet (Wegovy pill) approved on December 22, 2025, with a U.S. launch in early January 2026. It clarifies that Rybelsus is also oral semaglutide but is only approved for type 2 diabetes, making Wegovy the first oral GLP-1 specifically approved for chronic weight management. Results from the 71-week OASIS 4 trial showed average weight loss of 13.6% at a 25 mg dose versus 2.2% with placebo, with adherent patients closer to 16.6%. The script highlights strict dosing requirements (empty stomach, ≤4 oz water, wait 30 minutes), similar nausea side effects to injections, expected similar pricing, and ongoing insurance and adherence hurdles while noting improved access for those avoiding injections.00:00 Oral Wegovy Arrives00:35 What Makes It New00:53 OASIS 4 Results01:33 How to Take It01:58 Who Benefits Most02:28 Caveats and Costs02:49 Wrap Up | 2m 55s | ||||||
| 5/4/26 | Retatrutide, a Powerful New Weight Loss Drug in the Pipeline | Retatrutide Phase 3 Results: Major A1C Drops and 16.8% Weight Loss in Type 2 DiabetesThis Medical News Update covers late-stage trial results for retatrutide, an investigational weight-loss and diabetes drug from Eli Lilly. On March 19, 2026, Lilly announced positive topline findings from the phase 3 TRANSCEND-T2D-1 trial in adults with type 2 diabetes, showing A1C reductions of 1.7% to 2.0% depending on dose and average weight loss of 16.8% at the 12 mg dose. The script explains retatrutide’s three-hormone mechanism (GLP-1, GIP, and glucagon) versus Ozempic/Wegovy (GLP-1) and Mounjaro/Zepbound (GLP-1 + GIP), cautions that superiority claims require head-to-head trials, notes common side effects like nausea, vomiting, and diarrhea, and emphasizes that FDA approval, coverage, and pricing would still take significant time if future results remain strong.00:00 Big Drug News00:36 Trial Results Breakdown01:09 Why It Works01:38 Headlines Caveat02:03 What It Means02:25 Side Effects Tradeoffs02:38 When It Arrives02:54 Bigger Picture Wrap03:07 Final Sign Off | 3m 15s | ||||||
| 4/28/26 | Why Ozempic Sometimes Doesn't Work | Why Ozempic Doesn’t Work for Everyone: The DNA ClueThis episode explains why Ozempic and similar weight-loss drugs don’t work the same for everyone, highlighting a Stanford University study published in April 2026. Researchers found that about 10% of people carry variants in a single gene affecting the enzyme PAM, which helps activate the body’s natural GLP-1 hormone—the system these medications rely on. With a sluggish PAM “switch,” GLP-1 may not be properly activated, which could help explain why some patients lose a lot of weight while others see minimal results. The host offers three takeaways: lack of response may not be willpower-related, genetic testing may eventually guide drug choice, and non-responders should discuss alternatives like SGLT2 inhibitors with a doctor. The episode notes this is early research and no approved predictive test exists yet.00:00 Welcome and Setup00:20 Ozempic Works Differently00:43 The Gene Behind Response01:18 Why GLP-1 Drugs Vary01:38 Three Key Takeaways02:17 Early Research Caveats02:40 Wrap Up and Share | 2m 47s | ||||||
| 2/7/26 | How Metabolic Health Shapes the Brain, Blood Vessels, and Beyond | New Insights on Metabolic Health: Protect Your Brain and HeartIn this week's Medical News Update, we delve into recent research revealing how metabolic health impacts more than we realize. Key studies show that weight and blood pressure may contribute to dementia and heart issues, while redefining obesity could change our health landscape. We also highlight the effects of different types of fat on our blood vessels, the implications of post-meal blood sugar spikes on Alzheimer's risk, and the benefits of light physical activity for longevity. Keep your weight, blood pressure, and blood sugar in check with practical, everyday habits for long-term health benefits.00:00 Introduction to This Week's Medical News Update00:03 Metabolic Health and Dementia Risk00:57 Redefining Obesity: Beyond BMI01:45 The Role of Beige Fat in Heart Health02:36 Blood Sugar Spikes and Alzheimer's Risk03:31 Light Activity and Longevity04:13 Conclusion: Interconnected Health Factors#MetabolicHealth #DementiaPrevention #ObesityAwareness #BloodSugarControl #HealthyLifestyle | 4m 58s | ||||||
| 2/3/26 | High Dose Flu Vaccine Better Protection for Older Adults with Diabetes | In this episode of Medical News Update, we discuss a recent study from Denmark examining the efficacy of high-dose inactivated influenza vaccines in adults aged 65 and older, particularly those with diabetes. The study reveals that high-dose vaccines lead to fewer cardiorespiratory and cardiovascular hospitalizations compared to standard-dose vaccines. While the exact benefits vary, the findings suggest that a high-dose approach is beneficial for older adults, especially those with long-standing diabetes. The episode also highlights current CDC recommendations for flu vaccination in older adults.00:00 Introduction to Today's Topic00:03 The Importance of Flu Vaccination for High-Risk Groups00:17 Background on Influenza and Cardiovascular Risks00:45 Details of the Danish Study (DANFLU-2)01:45 Key Findings and Results03:43 Implications for Clinical Practice04:32 Conclusion and Final Thoughts | 5m 13s | ||||||
| 1/23/26 | BMI, blood pressure, and vascular dementia link | In this podcast episode, we discussWhat “vascular-related dementia” means and why blood flow mattersWhy Mendelian randomisation strengthens causal inference, and where it can misleadThe size of the BMI association and what the odds ratios implyHow much of the link may run through blood pressureWhat listeners can do now: knowing your numbers and seeking realistic supportSources mentionedThe Journal of Clinical Endocrinology and Metabolism (online publication: 22 January 2026)Endocrine Society press release (22 January 2026)Medical information in this podcast is for general education and is not personal medical advice.00:00 Introduction to Today's Topic00:03 New Research on Dementia and Body Weight00:36 Understanding the Study Methodology01:11 Key Findings: BMI and Dementia Risk01:53 Blood Pressure's Role in Dementia02:57 Implications for Everyday Life03:28 Practical Advice for Reducing Dementia Risk03:58 Conclusion and Further Reading | 4m 25s | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 11/15/25 | Medical News update: Smart Insulin and Dual‑Hormone Therapy | In this episode of Medical News Update, we explore innovative advancements in blood glucose regulation, focusing on smart insulin and dual-hormone therapy. Researchers at Indiana University School of Medicine have developed a fusion protein that combines insulin and glucagon, offering potential stability and effectiveness in managing blood sugar levels. Early animal studies show promise, but more research is needed before human clinical trials. Join us to learn how this could revolutionise type 1 diabetes care and make treatment more accessible globally. #DiabetesCare #InnovativeMedicine | 2m 45s | ||||||
| 9/10/25 | Semaglutide and Vision Loss: What You Need to Know | In today's episode, we discuss an important alert from the WHO regarding semaglutide medicines like Ozempic, Rybelsus, and Wegovy, which are used for type 2 diabetes and weight management. A rare but serious side effect called non-arteritic anterior ischemic optic neuropathy (NAY-on), leading to sudden vision loss, has been linked to these drugs. We review what the European Medicines Agency has found, the risks involved, and what patients should do if they experience vision changes. Awareness and prompt action are crucial. Learn more about how to manage these risks while benefiting from these medications.00:00 Introduction to Today's Episode00:01 Understanding Semaglutide Medicines00:17 Serious Side Effect Alert: NAY-on00:49 Risk Assessment and Recommendations01:45 Guidance for Patients on Semaglutide02:19 Conclusion | 2m 33s | ||||||
| 9/5/25 | Artificial Sweeteners and the Ageing Brain | Can diet sodas and sugar-free foods speed up brain ageing? A new study from the ELSA-Brasil cohort, published in Neurology, finds that artificial sweeteners are linked to faster memory and cognitive decline, especially in midlife adults and those with diabetes. In this episode, we break down the study, its strengths and limitations, and what it means for everyday dietary choices. | 2m 57s | ||||||
| 8/7/25 | Episode 10: Medical News update - Saliva Insulin Test, GLP-1 Policy Shift, and the DASH4D Diet | In this week’s episode, we explore:A potential saliva test for early diabetes risk detectionChildhood obesity rates rising over 250% since 2008GLP-1 drug usage patterns and a Medicare/Medicaid pilot programA new brain-targeted hormone approach for type 1 diabetesHow a modified DASH diet is helping people with type 2 diabetesAll information sourced from peer-reviewed studies:UBC Okanagan saliva insulin study - Applied Physiology, Nutrition, and MetabolismSevere pediatric obesity trends - JAMA Network Open, UC San DiegoGLP-1 usage patterns - RAND Corporation and KFF Health Tracking surveysMedicare/Medicaid coverage pilots - CMS policy announcementsLeptin therapy research - University of Washington, Journal of Clinical InvestigationDASH4D dietary intervention - Johns Hopkins, Nature Medicine and JAMA Internal Medicine | 4m 16s | ||||||
| 7/31/25 | Episode 9 Medical News Update The Role of Fasting in Diabetes Prevention and Management | Intermittent Fasting: A Breakthrough in Diabetes ManagementIn this episode, we explore the latest research on how occasional fasting can help manage diabetes. Learn about the benefits of intermittent fasting for blood sugar control, weight loss, and inflammation reduction. Discover how fasting, combined with modest exercise, can ease medication needs for people with type 2 diabetes. Tune in for practical insights and scientific findings that could transform your health routine.00:00 Introduction to Medical News Update00:07 Fasting and Diabetes: Recent Findings00:34 Practical Implications of Fasting00:53 Benefits of Fasting for Diabetes Management01:09 Clinician's Perspective on Fasting01:29 Conclusion and Take-Home Message01:40 Closing Remarks | 1m 49s | ||||||
| 2/14/25 | Episode 8: Medical News Update - : Broccoli Sprouts for Prediabetes, New Weight-Loss Drugs, and More! | Welcome to your Medical news update! Stay informed on the latest in diabetes and obesity research and prevention. In this episode, we discuss a study showing sulforaphane in broccoli sprouts can improve blood sugar levels in prediabetes, the impact of diabetes-related prejudice, next-gen weight-loss drugs, factors predicting diabetes progression, and the move to consider additional obesity metrics beyond BMI. Don’t forget to subscribe for the latest breakthroughs in health and science!00:00 Introduction to Medical News Update00:08 Sulforaphane and Blood Sugar Management00:26 Diabetes-Related Prejudice and Its Impact00:48 Next-Generation Weight-Loss Drugs01:06 Predictors of Diabetes Progression01:28 Rethinking Obesity Metrics01:48 Conclusion | 2m 01s | ||||||
| 12/24/24 | Episode 7: Medical News Update | In this episode of Medical News Update, we explore recent updates in the world of diabetes. Stay informed, stay healthy!00:00 Introduction 00:04 Stem Cell Therapy Breakthrough00:20 Impact of Early Dietary Choices00:33 Diabetes and Brain Health00:46 Global Diabetes Projections01:00 Conclusion and Sign Off | 1m 06s | ||||||
| 12/23/24 | Episode 6: FDA Approves First Drug Treatment for Obstructive Sleep Apnea in Adults with Obesity | In this episode of the Medical News Update, we discuss the FDA's approval of Zepbound (tirzepatide), a groundbreaking drug for treating moderate to severe obstructive sleep apnea in adults with obesity. Learn about the condition, how the medication works, clinical trial results, and potential risks and limitations. Stay informed about the latest medical advancements with our updates.00:00 Introduction to Medical News Update00:03 FDA Approves Zepbound for Obstructive Sleep Apnea00:27 Understanding Obstructive Sleep Apnea00:43 How Zepbound Works00:58 Clinical Trials and Results01:35 Considerations and Risks02:06 Conclusion and Final Thoughts02:22 Subscribe for More Medical Insights | 2m 33s | ||||||
| 11/30/24 | Episode 5: Stricter Blood Pressure Control for Type 2 Diabetes: New Findings | In this episode of the Medical News Update Podcast, we discuss a new study published in The New England Journal of Medicine. The study explores how more rigorous blood pressure control can help type 2 diabetes patients avoid serious heart issues. | 2m 30s | ||||||
| 6/17/24 | Episode 4: Medical News Update: The Impact of Ultra-Processed Plant-Based Foods on Health | In this episode of Medical News Update, we explore the impact of ultra-processed foods on cardiovascular health, particularly within plant-based diets. Emerging research unveils the risks associated with these industrially formulated foods, highlighting their link to increased heart disease and mortality. Join us as we discuss significant findings from various studies and learn why whole foods are essential for a heart-healthy diet.00:00 Introduction to Ultra-Processed Foods and Cardiovascular Health00:40 Understanding Ultra-Processed Foods01:21 Research Findings on Ultra-Processed Foods02:08 Impact of Plant-Based Diets on Cardiovascular Health02:37 Detailed Study Insights03:42 Health Risks of Plant-Based Ultra-Processed Foods04:39 Conclusion | 5m 20s | ||||||
| 6/3/24 | Episode 3: Cannabis Use and Cardiovascular Risks: New Study Findings | Medical News Update | Cannabis Use and Cardiovascular Risks: New Study Findings | Medical News UpdateIn this episode of the Medical News Update, we delve into a 2024 study published in the Journal of the American Heart Association that investigates the relationship between cannabis use and cardiovascular health in U.S. adults. The study found increased risks of heart disease, heart attacks, and strokes among regular cannabis users, with risks rising with usage frequency. Data from over 434,000 respondents aged 18-74 years was analyzed, revealing higher cardiovascular risks even among non-tobacco smokers. The episode emphasizes the importance of awareness and screening for cardiovascular risks associated with cannabis use.00:00 Introduction to the Medical News Update00:04 Study Overview: Cannabis Use and Cardiovascular Health00:38 Study Methodology and Data Collection01:10 Key Findings: Prevalence and Risks of Cannabis Use01:30 Detailed Risk Analysis for Cannabis Users02:02 Risks Among Non-Tobacco Smokers02:35 Study Limitations and Implications03:01 Conclusion and Health Recommendations03:08 Closing Remarks | 3m 20s | ||||||
| 4/27/24 | Episode 2: Medical News Update 27/04/2024 | This episode of the Medical News Update covers several studies on managing diabetes and heart health and promising malaria prevention treatments in children. Initial findings suggest afternoon exercise may temporarily aid in managing blood sugar levels in type 2 diabetes patients, while cinnamon consumption could potentially improve blood glucose control in those with prediabetes. Additionally, regular avocado intake may be linked to a lower diabetes risk among Mexican adults. The trial on empagliflozin post-heart attack shows some potential benefits despite not meeting its primary endpoint, whereas a new monoclonal antibody significantly reduces malaria risk in children. Each study points toward exciting directions for future research, with implications for dietary interventions and pharmaceutical treatments in managing and preventing these conditions.00:00 Welcome to Medical News Update00:29 Impact of Exercise Timing on Blood Sugar Levels01:18 Cinnamon's Effect on Blood Glucose in Prediabetes02:00 Avocado Consumption and Diabetes Risk02:54 Empagliflozin's Role in Heart Failure Post-Heart Attack03:57 Monoclonal Antibody Against Malaria in Children04:47 Closing Remarks | 4m 59s | ||||||
| 4/13/24 | Episode 1: Medical Insights Beta Blockers in Post Heart Attack Care | We explore the surprising findings from a recent study on beta-blockers' effectiveness for patients with normal heart function post-heart attack. Join us as we discuss what these results could mean for future treatments and patient care.Don't forget to like, comment, and subscribe for more insightful updates!#HealthNews #MedicalInsights #MedicalResearch #HealthcareUpdatesReferences:Yndigegn T, Lindahl B, Mars K, et al. Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction. N Engl J Med. 2024;381:1707-1717. DOI: 10.1056/NEJMoa2401479. | 2m 37s | ||||||
Showing 23 of 23
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
5 placements across 5 markets.
Chart Positions
5 placements across 5 markets.